ALSO NOTED: Dr. Reddy's raising $260M; Alexion wins priority review; new data supports orencia; and much more...

> The generic drug maker Dr. Reddy's Laboratories plans to raise $260 million through an issue of 13.5 million American Depositary Shares. The Indian company has been on an acquisition spree, acquiring Germany's Betapharm in March as it pursued a strategy of expanding in the European market. Report

> The FDA has agreed to provide a priority review of Alexion Pharmaceuticals' anemia drug eculizumab. Report

> Bristol-Myers Squibb is touting new data that shows orencia helped improve a form of arthritis in children. Report

> Regeneron Pharmaceuticals, which is researching new therapies for cancer and eye and inflammatory diseases, plans to offer 7.6 million common shares. Release

> Roche's Tamiflu will carry new warnings about delirium. Report

> Cancer diagnostic company Zila has signed agreements for a $40 million private placement. Release

> DeCODE genetics is proposing to make an offering of 3.5% senior convertible notes due 2011. Release

> Spectrum Pharmaceuticals announced that it has settled a patent dispute with Glaxo over a generic version of Imitrex injection. Report

> Huifeng Bio-Pharmaceutical announced today that it has agreed to purchase two production lines of a Chinese corporation in exchange for 2 million newly issued shares of Huifeng restricted stock. Release

And Finally… Researchers in Sweden provided free junk food to students to test the effects of a high-fat diet. They gained weight, but their bodies swiftly adjusted to the change. Article

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.